Abstract We investigated the clinical performance of a polymerase chain reaction (PCR)-based commercial platform, the Myconostica MycAssay™ Aspergillus (MAP), for fungal DNA detection in the serum of patients at risk of invasive aspergillosis (IA). Sixty-four hospitalized patients were prospectively enrolled and a total of 71 different episodes were investigated (30 episodes were clinically/ microbiologically classified as IA and 41 as control episodes). When MAP was compared to the galactomannan (GM) assay, no significant differences were found in terms of sensitivity (46.7 % vs. 50.0 %), specificity (97.6 % vs. 95.1 %), positive predictive value (PPV) (93.3 % vs. 88.2 %), and negative predictive value (NPV) (71.4 % vs. 72.2 %). The corresponding areas under the curve (AUC) of the receiver operating characteristic (ROC) curves were also superimposable. Overall, because of the good agreement between the two assays and considering the high specificity and PPV of the MAP, we suggest the use of this PCR-based platform as a second-level examination for the evaluation of clinically undefined cases where culture or GM have provided positive results.
Introduction
Aspergillus spp. is a ubiquitous fungus that can behave as an opportunistic pathogen in humans; particularly, A. fumigatus is responsible for about 90 % of aspergillosis, whose overall lethality ranges between 40 and 90 % [1] [2] [3] [4] , also depending upon the time when therapy is started [5] . To date, conventional microbiological approaches to the diagnosis of invasive fungal diseases (IFD), such as microscope-and culture-based analysis, are not suitable to guide early targeted therapy, because of the low sensitivity and the long times to result. In contrast, the employment of non-cultural methods, particularly those allowing fungal antigens detection, such as galactomannan (GM) [6, 7] , 1-3-beta-D-glucan (BG) [8, 9] , and fungal DNA by polymerase chain reaction (PCR)-based assays [10] , may greatly shorten the time to diagnosis and, consequently, allow early and targeted therapy. Hopefully, such non-cultural methods may also allow to reduce empiric treatment in patients at risk of IFD, currently recommended by guidelines [Third European Conference on Infections in Leukemia (ECIL3) [11] for hematological patients and Surviving Sepsis Campaign [12] for intensive care unit (ICU) patients]. Nowadays, thanks to the good performance of standardized commercial platforms, both the GM and BG detection are included as criteria for the definition of IFD, according to the revised European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) [13] . In contrast, PCR-based methods for the detection of fungal DNA have not been included as reference tests yet, due to the lack of standardization. Recently, commercial Aspergillus CE-IVD marked real-time PCR kits have been made available, with protocols allowing fungal DNA assessment not only in bronchoalveolar lavage (BAL) but also in serum. This opens the door to a diffuse use of such platforms, that, in turn, will likely allow a proper clinical validation.
Here, we describe a single-center prospective clinical study that investigates the clinical performance of the commercial real-time PCR-based assay, MycAssay™ Aspergillus (MAP, from Myconostica, now a Trinity Biotech company, Kentford, UK), for the search of fungal DNA in serum samples.
Materials and methods

Patients
In this study, we investigated patients who had been hospitalized during the period from December 2011 to December 2013 at the Azienda Ospedaliero-Universitaria (AOU) Policlinico di Modena. According to the clinicians, 71 patients were considered at risk or with a suspicion of invasive aspergillosis (IA); 64 of them were prospectively enrolled in the study, while the remaining seven patients were excluded for incomplete data collection. In the hematological population, patients were considered at risk of IA when they had, or they were at risk of, prolonged neutropenia (more than 7 days). For the non-hematological patients, a clinical picture of pneumonia (i.e., symptoms of lower respiratory tract infections and a new infiltrate without an alternative diagnosis) was requested and, in addition, at least one host factor [chronic obstructive pulmonary disease (COPD), cirrhosis, cancer receiving chemotherapy, solid organ transplant, human immunodeficiency virus (HIV) infection, steroid use]. Furthermore, the clinical suspicion of IFD was defined as a clinical picture of pneumonia plus a positive microbiological test for IA (microscopic examination, culture, or GM on serum or BAL specimens).
Of the 64 patients, six had been hospitalized twice and one patient three times; according to the new clinical suspicion of IA, each event was operationally defined as a different episode and, as such, included in the study. At the end of the enrolment, a total of 71 episodes were investigated and operationally clustered into two groups: the IA group and the control (CTRL) group. For hematological patients, the classification was made on the basis of the EORTC/MSG criteria [13] ; for the other patients, the modified criteria proposed by Meersseman et al. [14, 15] and used by Torelli et al. [16] were applied; such criteria included cirrhosis, COPD, and steroids at low dosage as host factors, together with clinical criteria that also included symptoms of lower respiratory tract infection (e.g., dyspnea), pleural rub, and new infiltrate without an alternative diagnosis. To enhance the robustness of the analysis, only the proven or probable IA episodes were allocated to the IA group. The present study was approved by the local ethical committee (no. 53/11).
Samples
Serum samples were obtained from blood, after centrifugation at 5,000 rpm for 5 min; the samples were stocked at −80°C until analysis. For each episode, several serum samples were harvested and processed. A total of 141 serum samples were collected and analyzed.
Conventional microbiological assays
According to the clinicians' requests, the conventional diagnostic tests for IA were performed at the Microbiology and Virology Unit of the AOU Policlinico of Modena. In detail, microscopic examination of Gram-stained samples, cultural analysis, and GM antigen (GM, Platelia Aspergillus Ag; BioRad, Marnes-la-Coquette, France) research on both BAL and serum specimens were assessed. According to the manufacturer's instructions, GM-positive results were determined using an optical density (OD) index≥0.5 as a cut-off value.
PCR-based analysis
Fungal DNA was extracted from 0.5 ml of serum sample using the High Pure PCR Template Preparation Kit (Roche Diagnostics GmbH, Mannheim, Germany), with the modified protocol provided in the MAP kit. Aspergillus spp. DNA in the extracted samples was assessed by the MAP kit, a qualitative real-time PCR assay based on molecular beacons technology that is able to amplify an Aspergillusspecific region of the multicopy 18S rRNA gene. The amplification process was carried out on the SmartCycler platform (Cepheid, Sunnyvale, CA, USA), using a 39-cycle threshold as a cut-off value, as established by the manufacturer. The kit included positive, negative, and internal controls (IC) for the amplification step only.
Statistical analysis
The mean, standard deviation, and range were calculated for continuous variables. To assess differences, the t-test was used for comparing continuous variables, the χ 2 or Fisher's exact test were used for independent binomial variables, and McNemar's test was used for dependent binomial variables; the null hypothesis was rejected for a p-value<0.05.
The diagnostic performances of the MAP and GM assays were evaluated by receiver operating characteristic (ROC) curve analysis, estimation of the areas under the curve (AUC), and estimation of their 95 % confidence intervals (CIs). The sensitivity, specificity, positive predictive values (PPVs), and negative predictive values (NPVs) were calculated and the 95 % CI for binomial variables were estimated using the Clopper-Pearson exact distribution. Accuracy and kappa were calculated to assess the concordance between tests.
Results
The 64 patients included in the study were equally distributed between genders (50 % males and 50 % females). The average age was 59±16, with a range of 19-82 years. During the investigation period, such patients experienced a total of 71 different episodes, which were independently assessed by means of 141 serum samples. As depicted in Table 1 , 55 out of 71 episodes (77.5 %) occurred in subjects with hematological diseases, while 7 out of 71 episodes (9.9 %) occurred in patients with respiratory diseases. Operationally, as detailed in the "Materials and methods" section, the 71 episodes were clustered into two groups: the IA group (30 episodes) and the CTRL group (41 episodes). As shown by the p-values, there were no significant differences between the two groups in terms of clinical features, such as hospital ward, underlying disease, antifungal therapy, and non-IA infections. Twentyeight out of the 30 IA episodes were diagnosed as probable IA, while the remaining two episodes were diagnosed as proven IA. In 26 out of 30 IA episodes, BAL specimens were available for culture analysis and they returned positive results in 18 out of 26 episodes. In particular, ten were culturepositive for A. fumigatus, seven were culture-positive for A. flavus, and only one was culture-positive for A. niger. The assessment of GM, which was performed on 22 BAL samples only, always returned positive results; of the eight remaining episodes not assessed for GM, four resulted culture-positive and four serum GM-positive. It should be noted that the latter were observed in four neutropenic and febrile hematological patients [two acute myeloid leukemia (AML) and two acute lymphoblastic leukemia (ALL)], with suggestive radiological findings of IA; in these cases, BAL samples were not collected due to the severe conditions of the patients. Moreover, when considering the CTRL group, we found that 12 out of 16 CTRL episodes were negative for BAL GM and 39 out of 41 were negative for serum GM; none of those assessed resulted positive in the BAL culture analysis. Table 2 summarizes the results of the MAP and GM assays according to the IA versus CTRL classification; data were aggregated considering as a positive result at least one positive serum sample within each episode. The MAP assay resulted positive in 14 out of 30 IA episodes and negative in 40 out of 41 CTRL episodes. The GM assay resulted positive in 15 out of 30 IA episodes and negative in 39 out of 41 CTRL episodes. In particular, 13 out of the 15 GM-positive episodes were also MAP-positive (including the four IA episodes, for which the BAL samples had not been collected). Two IA episodes were GM-positive and MAP-negative, while one IA episode was MAP-positive and GM-negative. In 2 out of the 13 IA episodes that were positive in both assays, the MAP became positive 3 and 4 days, respectively, before the GM determination. For 1 of the 2 proven IA episodes, both assays returned positive results, while for the other episode, both the MAP and the serum GM were negative in all three serially tested samples. This episode was from a hematopoietic stem cell transplantation (HSCT) recipient patient with a diffuse large B cells lymphoma, whose BAL resulted positive for both the GM assay and culture (A. flavus). The patient had positive EORTC/MSG criteria for molds tracheobronchitis at bronchoscopy (ulceration plus eschar), which was confirmed by positive biopsy for Aspergillus.
According to the data described above, the performance of the MAP and GM assays are reported in Table 3 ; no significant differences were found between the MAP and GM assays in terms of the sensitivity (46.7 % vs. 50.0 %), specificity By focusing the analysis on the hematological patients (in particular, on those 15 IA episodes for which both GM and MAP assays were performed at the onset of the IA), the sensitivity of the MAP increased to 60 % (32-84). Also, in these cases, no significant differences were observed between the MAP and serum GM results (data not shown). Finally, in 8 out of these 15 episodes, patients were under mold-active treatment (four prophylactic, three empiric, and one targeted); when tested by the MAP assay, positive results were observed in 5 out of 8 episodes of the treated patients and in 4 out of 7 episodes of the non-treated patients.
Discussion
In the present study, we evaluated the clinical performance of the MycAssay™ Aspergillus, a new commercially available real-time PCR platform for the detection of Aspergillus spp. DNA in serum samples. With the aim of resembling as much as possible the conditions of the routine diagnostic, the platform has been employed in parallel with the conventional diagnostic tests routinely used in our hospital. The clinical frame consisted of a heterogeneous group of patients, from different wards, at risk or with suspicion of IFD, as established by clinicians. In many cases, patients were enrolled at the first positive microbiological test (especially the non-hematologic patients). Such an approach in selecting patients, together with the post-2012 earthquake refurbishment of the hospital during the enrolment period, may partially explain the high incidence of IFD (42 %) observed in our population.
Our results indicate that the MAP assay has a good overall performance and a high degree of concordance with the current serum standard GM assay, in line with the results of a recent retrospective study [17] . However, the sensitivity obtained in our study appears to be lower (46.7 %) compared to the sensitivity reported by White et al. (70 %); this may have different explanations. First, different protocol designs have been employed in the two studies, namely, a prospective versus a retrospective enrolment. Commonly, the latter, as used by White et al. [17] , retains several biases, including the possibility of losing borderline episodes. Second, there are differences in the patients enrolled for the studies: White et al. investigated hematological patients only, while we have extended the study to all the patients at risk or with a suspicion of IA, irrespective of the basal disease. It is worth noting that, when we considered only the hematological patients, the sensitivity of the MAP platform increased from 46.7 % (28-66) to 60 % (32-84), reaching values much closer to those reported by White et al. [17] . Furthermore, according to the local and international guidelines, our patients were under a mold-active treatment in about half of the investigated IA episodes. In this respect, the initial literature describes a negative association between mold-active treatment and the sensitivity of diagnostic assays for IA, particularly the GM assay on serum [18, 19] . It remains to be established whether the performance of PCR-based assays as well may be impaired by the use of mold-active treatment, as recently claimed [20] , or, rather, if it remains unaffected. Our limited, but consistent, set of data shows no difference between treated and untreated patients (six MAP-positive out of fourteen untreated patients; seven MAP-positive out of sixteen treated patients), supporting, thus, a lack of correlation between mold-active treatment and PCR-based assay sensitivity.
The employment of serum samples has the advantage of allowing the use of simple, commercial, and possibly automated DNA extraction procedures, capable of high analytical sensitivity (up to 5 genome copies/0.5 ml of sample) [21] . Nevertheless, when employing serum, any host cellassociated fungal DNA is lost during blood fractionation. At present, we cannot exclude that this technical aspect may also partially account for the low clinical sensitivity of the MAP assay. Whether and to what extent the employment of different biological matrices may affect the performance of PCR-based diagnostic platforms is still a matter of debate and controversial data have been provided so far. On the one hand, in a recent multicenter prospective study using a whole-blood approach [22] , a relevant increase in the number of positive samples has been reported. On the other hand, the European Aspergillus PCR Initiative shows only a slight difference in the performance of PCR-based assays when employing blood or serum samples [21, 23] .
Increasing evidence describes the good performance of real-time PCR-based platforms when employing BAL as a matrix representative of the site of primary infection. In particular, a meta-analysis study returned a mean sensitivity of 87 % (79-92) [10] , increased to values ranging from 94 % (68-100) to 100 % (54-100) when a similar platform, set up by Myconostica for Aspergillus DNA detection in BAL specimens [16, 24, 25] , was employed. Thus, these findings underline the efficacy of PCR-based platforms, especially when performed on biological matrices such as BAL. It remains to be established whether the sensitivity of these same platforms applied to a peripheral specimen, such as blood, may be further enhanced by partially modifying the protocol (i.e., increased volumes, use of buffy coats, etc.). In our opinion, also, the inclusion of an internal control for DNA extraction, currently not present in the assay, may represent a further step ahead towards a better performance of the platform. Any progress in this direction would facilitate IA diagnosis by the use of a much easier and routinely available sample, such as blood, with respect to BAL. Thus, large-scale screening as well as prolonged monitoring of patients at risk of IA might become possible via a non-invasive sampling.
In line with a recent report [17] , our study describes high levels of concordance between the MAP and GM assays when performed in serum samples. Interestingly, this occurs irrespective of the underlying disease or of the concomitant antifungal treatment. The agreement between the two assays occurs also in terms of negative results, as obtained by both the MAP and the GM assays, in the episode of proven Aspergillus tracheobronchitis observed here. Considering that antigenemia is known to be lower in patients with pulmonary aspergillosis than in patients with angioinvasive disease [26] , we favor the hypothesis that, also, Aspergillus DNAemia may follow a similar trend, as recently suggested [27] , thus accounting for the negative results observed in such clinical cases.
Overall, our study provides an initial forward step towards the clinical validation of the MAP assay, that, indeed, shows levels of performance comparable to those of the cultureindependent gold standard GM assay on serum. While a routine and large-scale use of this PCR-based platform will likely depend on the optimization of the protocol and possibly on the automation of the procedure, the employment of the MAP assay in reference laboratories should be strongly recommended as a second-level examination: because of its high specificity and PPV, the assay may help greatly in cases where dubious culture-or GM-positive results in serum and/or BAL are not supported by a typical clinical or radiological picture.
